Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Phase EARLY_PHASE1 Completed

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive

NCT07458919 2026-03-09

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Phase EARLY_PHASE1 Not yet recruiting

94 enrolled

Thoracic

Lung Neoplasms

NCT03164486 2026-02-27

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Phase EARLY_PHASE1 Active not recruiting

27 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07235280 2026-02-19

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

Phase EARLY_PHASE1 Recruiting

48 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT05493566 2026-02-12

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Phase EARLY_PHASE1 Recruiting

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05620342 2026-02-05

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Phase EARLY_PHASE1 Recruiting

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT07236177 2026-02-05

B-GLUCANCER2

Phase EARLY_PHASE1 Recruiting

220 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

Clinical Trials

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Therapy for Advanced NSCLC With EGFR 19delins Mutation

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

B-GLUCANCER2